The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: EnQuest falls on production output warning

Thu, 02nd Sep 2021 10:55

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

----------

SMALL-CAP - WINNERS

----------

Tiziana Life Sciences PLC, up 18% at 72.35 pence, 12-month range 46.44p-206.00p. The clinical stage biotechnology company alongside US peer Precision BioSciences announce an exclusive license agreement to evaluate Tiziana's Foralumab, an anti-CD3 monoclonal antibody in conjunction with allogeneic CAR T candidates for cancer treatment. The companies would explore Foralumab as an agent to induce tolerance of allogeneic CAR T cells to potentially improve the clinical outcome of CAR T cell therapy. Under the terms, Tiziana will receive upfront payment, certain milestone payments, and royalties for Foralumab.

----------

Gym Group PLC, up 3.4% at 292.58 pence, 12-month range 116.00p-317.50p. The no-frills gym chain reports rise in membership as restrictions ease. For the six months ended June 30, pretax loss barely narrows to GBP28.5 million from GBP28.6 million the year before, as administrations costs remain high at GBP54.6 million, and revenue declines 21% to GBP29.3 million from GBP37.3 million. However, membership numbers at the end of June rose to 730,000 from 698,000 a year prior. Looking ahead, membership numbers at the end of August dipped to 721,000 from June, but sees higher membership levels in September and October as students return to universities. "Despite the significant disruption caused by the pandemic, Gym Group is well placed to continue its steady recovery and plans for growth as it capitalises on a return to more normal activity," says Edison analyst Richard Finch.

----------

SMALL-CAP - LOSERS

----------

EnQuest, down 7.7% at 23.30p, 12-month range 8.67p-26.95p. The oil and gas firm reports narrowed first half loss, but warns full-year production will be at the lower end of the guidance range. For six months to June 30, its profit after tax narrowed to USD56.4 million from a USD472.4 million loss last year. Looking ahead, EnQuest sees 2021 average net production at the lower end of the guidance range of 46,000 barrels of oil equivalent per day and 52,000 boepd. This reflects expected performances at Magnus, the Greater Kittiwake Area and PM8/Seligi over the course of the second half of the year, it says.

----------

SDCL Energy Efficiency Income Trust PLC, down 3.7% at 113.17p, 12-month range 104.50p-119.00p. The investment company intends to raise GBP175 million via a share issue at 110.50p each, which is 6.0% discount to Wednesday's closing share price of 117.50p.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
7 Feb 2019 11:40

Tiziana Life Sciences Non-Exec Director Riccardo Dalla-Favera Resigns

LONDON (Alliance News) - Tiziana Life Sciences PLC on Thursday said Non-Executive Director Riccardo Dalla-Favera has resigned from his role."The company is grateful to Favera for his

Read more
3 Dec 2018 14:27

Tiziana completes patient enrolment in ongoing Milciclib study

(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Monday that patient enrolment in its ongoing Phase 2a clinical trial, known as CDKO-125A-010, was now completed.

Read more
3 Dec 2018 11:51

Tiziana Life Completes Patient Enrollment In Liver Cancer Trial

LONDON (Alliance News) - Tiziana Life Sciences PLC on Monday said it completed patient enrollment in a Phase 2a trial of Milciclib in hepatocellular carcinoma.The company explained that the

Read more
28 Nov 2018 12:19

Tiziana Life Sciences Begins First-In-Human Phase 1 Trial Of Foralumab

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday said it began the first in-human trial of Foralumab, a treatment for autoimmune diseases.The biotechnology company said the a

Read more
20 Nov 2018 12:53

Tiziana Life Sciences Prices ADS Offering, Raises GBP3.4 Million

LONDON (Alliance News) - Tiziana Life Sciences PLC said Tuesday that it has priced its underwritten public offering in the US of 442,910 American Depositary Shares representing ordinary shares in

Read more
25 Sep 2018 13:43

Tiziana Life Seeks Listing Of ADS On Nasdaq Capital Market (ALLIPO)

LONDON (Alliance News) - Tiziana Life Sciences PLC said Tuesday that it has commenced underwritten public offering in the US of American Depositary Shares representing ordinary shares in the UK of

Read more
24 Sep 2018 12:37

Tiziana Half-Year Loss Unchanged; Gets US Approval For Foralumab Trial

LONDON (Alliance News) - Tiziana Life Sciences PLC on Monday reported a flat loss in the first half of 2018 as expenses were broadly unchanged, while the biotechnology firm also announced that its

Read more
17 Aug 2018 11:39

DIRECTOR DEALINGS: Tiziana Life Chairman Associate Buys Shares

LONDON (Alliance News) - Tiziana Life Sciences PLC said Friday that Panetta Partners Ltd, a company associated with Chairman Gabriele Cerrone, bought shares in the company worth acquired 469,766 a

Read more
16 Aug 2018 11:47

Tiziana seeks trial for multiple sclerosis 'game changer'

(Sharecast News) - Tiziana Life Sciences on Thursday submitted an application to initiate phase one clinical trials for a new treatment of neurodegenerative diseases to the US food and drug administration.

Read more
27 Jul 2018 11:14

Tiziana Life Sciences Files For IPO Of American Depositary Shares (ALLIPO)

LONDON (Alliance News) - Tiziana Life Sciences PLC said Friday it filed a registration statement with the US Securities Exchange Commission for a proposed initial public offering of its American

Read more
16 May 2018 13:27

Tiziana Life Science Reports Progress In Milcicib Phase 2a Trial

LONDON (Alliance News) - Biotechnology company Tiziana Life Sciences PLC said Wednesday that the phase 2a trial of Milciclib safety and tolerability in patients with Metastatic Hepatocellular has

Read more
19 Apr 2018 14:44

Tiziana Raises GBP825,000 Through Placing Of 1 Million Shares (ALLISS)

LONDON (Alliance News) - Tiziana Life Sciences PLC said Thursday it has raised GBP825,000 from the issue of 1.0 million new shares at a price of 80 pence per share.The cancer and autoimmune

Read more
4 Apr 2018 12:53

Tiziana Appoints Leopoldo Zambeletti As Non-Executive Director

LONDON (Alliance News) - Tiziana Life Sciences PLC, a biotechnology company developing drugs for cancer and autoimmune diseases, said Wednesday Leopoldo Zambeletti has joined

Read more
16 Nov 2016 09:34

Tiziana Life Sciences makes breakthrough oral treatment for inflammatory diseases

(ShareCast News) - Tiziana Life Sciences, the clinical stage biotechnology company, announced that new data has demonstrated the potential of its novel oral therapy with foralumab for non-alcoholic steatohepatitis (NASH), diabetes and other life threatening inflammatory diseases. Oral efficacy in hu

Read more
18 Jul 2016 12:03

Tiziana Life looks for secrets of long life with new acquisition

(ShareCast News) - Tiziana Life Sciences has purchased key assets from Sardinia-based biobanking and genomics research company Shardna for €258,000, giving it access to the genetic data of nearly 13,000 people from the Ogliastra region, where life expectancy is high. The AIM-listed clinical stage bi

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.